Search the Site
Follow TheCancerLetter on Twitter
join our mailing list

Enter your name and email address to receive an update when we post new content.

IP Login

 

The Cancer Letter Inc.
PO Box 9905
Washington
DC 20016
Tel: 202-362-1809
Fax: 202-379-1787
publication date: Jun 2, 2016
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

NCI CTEP-Approved Trials for the Month of May

 

The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.

 

Phase I

9899: A Phase 1 Trial of the Combination of the Heat Shock Protein-90 (HSP90) Inhibitor Onalespib (AT13387) and the Cyclin-Dependent Kinase (CDK) Inhibitor AT7519M in Patients with Advanced Solid Tumors. Dana-Farber - Harvard Cancer Center LAO; Do, Khanh Tu. (617) 632-6992

 

9930: A Phase I Trial of MEDI-570 in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) Follicular Variant and Angioimmunoblastic T-Cell Lymphoma (AITL). University Health Network Princess Margaret Cancer Center LAO; Chavez, Julio C. (813) 745-1867

 

Phase II

9875: Phase 2 Study of AT13387 (onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL. Dana-Farber - Harvard Cancer Center LAO; Jacobson, Caron Alyce. (617) 582-7591

 

9881: A Phase 2 Study of Cediranib in Combination with Olaparib in Advanced Solid Tumors. Yale University Cancer Center LAO; Kim, Joseph Woong. (203) 737-1600

 

Phase III

EA5142: Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers. ECOG-ACRIN Cancer Research Group; Chaft, Jamie Erin. (646) 888-4543

 

Other Phases

10018: Randomized Trial of Financial Incentives for Research Participation. University of Pennsylvania/Abramson Cancer Center; Halpern, Scott David. (215) 898-1462

 

ACNS14B2-Q: Examination of Molecular Alterations of Potential Diagnostic, Prognostic and Therapeutic Utility Among Pediatric Low-Grade Gliomas (PLGGs) Treated on the Children’s Oncology Group Clinical Trial, A9952. Children’s Oncology Group; Eberhart, Charles G. (410) 502-5185

 

AOST15B2-Q: Validation of a Plasma MicroRNA Panel as a Biomarker for Osteosarcoma. Children’s Oncology Group; Allen-Rhoades, Wendy (832) 824-4207

 

ARST16B1-Q: Utilizing the Collaborative PedsTCC Infrastructure Towards Molecular Discovery of Novel Translocations and the Exomic Mutational Landscape in Embryonal Sarcoma. Children’s Oncology Group; Setty, Bhuvana Anantha. (614) 722-3550

 

ARST16B2-Q: Investigating the Role of the Transcriptional Co-Activator TAZ (Transcriptional Co-Activator with PDZ-Binding Motif) in Alveolar Rhabdomyosarcoma. Children’s Oncology Group; Linardic, Corinne Mary. (919) 684-3401

 

EAQ152: COMET - Communication and Education in Tumor Profiling: A Randomized Study of Pre-Disclosure Genetic Education v. Usual Care in Tumor Profiling for Advanced Cancer and a Pilot Study of Remote Genetic Counseling for Participants with Potential Germline Mutations Identified on Tumor Profiling. ECOG-ACRIN Cancer Research Group; Bradbury, Angela R. (215) 615-3341



To access this members-only content, please log in.

If you're not a subscriber why not join today?

If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Letter